The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kukushkin M.L.

Research Institute of General Pathology and Pathophysiology

Amelin A.V.

Pavlov First St. Petersburg State Medical University

Akhmedzhanova L.T.

Sechenov First Moscow State Medical University (Sechenov University);
Academy of Interventional Medicine

Barantsevich E.R.

Pavlov First St. Petersburg State Medical University

Barulin A.E.

Volgograd State Medical University

Beniashvili A.G.

Scientific Center of Mental Health

Davydov O.S.

Research Institute of General Pathology and Pathophysiology

Danilov An.B.

Sechenov First Moscow State Medical University (Sechenov University)

Devlikamova F.I.

Kazan State Medical Academy

Zhivolupov S.A.

Kirov Military Medical Academy

Iskra D.A.

St. Petersburg State Pediatric Medical University

Kamchatnov P.R.

Pirogov Russian National Research Medical University

Karakulova Yu.V.

Wagner Perm State Medical University

Karpova M.I.

South Ural State Medical University

Kozlov I.G.

Sechenov First Moscow State Medical University (Sechenov University);
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology;
Sechenov First Moscow State Medical University (Sechenov University)

Kurushina O.V.

Volgograd State Medical University

Rachin A.P.

National Association of Experts in Comorbid Neurology

Sivolap Yu.P.

Patrice Lumumba Peoples’ Friendship University of Russia

Churyukanov M.V.

Sechenov First Moscow State Medical University (Sechenov University);
Petrovsky National Research Center of Surgery

Shirokov V.A.

Ural State Medical University

Yakupov E.Z.

Professor Yakupov’s Neuroclinic, Professor Yakupov’s Education Center

Back pain: empirical and personalized approach to drug therapy. Conclusion of the Expert Council of the Russian Society for the Study of Pain

Authors:

Kukushkin M.L., Amelin A.V., Akhmedzhanova L.T., Barantsevich E.R., Barulin A.E., Beniashvili A.G., Davydov O.S., Danilov An.B., Devlikamova F.I., Zhivolupov S.A., Iskra D.A., Kamchatnov P.R., Karakulova Yu.V., Karpova M.I., Kozlov I.G., Kurushina O.V., Rachin A.P., Sivolap Yu.P., Churyukanov M.V., Shirokov V.A., Yakupov E.Z.

More about the authors

Journal: Russian Journal of Pain. 2025;23(1): 92‑98

DOI: 10.17116/pain20252301192

Read: 920 times

Download PDF (RU)
Contact the author
Table of contents

BACK PAIN: EMPIRICAL AND PERSONALIZED APPROACH TO DRUG THERAPY. CONCLUSION OF THE EXPERT COUNCIL OF THE RUSSIAN SOCIETY FOR THE STUDY OF PAIN
BACK PAIN: EMPIRICAL AND PERSONALIZED APPROACH TO DRUG THERAPY. CONCLUSION OF THE EXPERT COUNCIL OF THE RUSSIAN SOCIETY FOR THE STUDY OF PAIN

To cite this article:

Kukushkin ML, Amelin AV, Akhmedzhanova LT, et al. . Back pain: empirical and personalized approach to drug therapy. Conclusion of the Expert Council of the Russian Society for the Study of Pain. Russian Journal of Pain. 2025;23(1):92‑98. (In Russ.)
https://doi.org/10.17116/pain20252301192

Подписка 2025 Российский журнал боли (Russian Journal of Pain)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Reso­lution of the exte­nded meeting of the Presidium and committees of the Russian Asso­ciation for the Study of Pain (RASP) “The role of central muscle rela­xants in the treatment of non-specific low back pain”. Russian Journal of Pain. 2025;(2):91-91
Abstract:

OBJECTIVE

To present the recommendations of the expert council of the Russian Society for the Study of Pain on “Dorsumio” drug in the treatment of chronic nonspecific back pain (CNBP).

KEY POINTS

Currently, CNBP is the leading disease associated with disability worldwide. Patients with CNBP often experience concomitant depressive and anxiety symptoms complicating the course of disease and therapy, as well as worsening the quality of life and working capacity. Various problems in care for CNBP include not only the impact on pathogenesis of chronic pain, but also treatment of depression, anxiety, insomnia, assessment of compatibility of various drugs and patient adherence to therapy. The new drug “Dorsumio” (mirtazapine 15 mg + tizanidine 6 mg) can influence on chronic pain mechanisms and provide effective therapy for patients with chronic nonspecific back pain due to complex analgesic, muscle relaxant, antidepressant and anti-anxiety effects.

Keywords:

central muscle relaxants
“Dorsumio”
chronic nonspecific back pain

Authors:

Kukushkin M.L.

Research Institute of General Pathology and Pathophysiology

Amelin A.V.

Pavlov First St. Petersburg State Medical University

Akhmedzhanova L.T.

Sechenov First Moscow State Medical University (Sechenov University);
Academy of Interventional Medicine

Barantsevich E.R.

Pavlov First St. Petersburg State Medical University

Barulin A.E.

Volgograd State Medical University

Beniashvili A.G.

Scientific Center of Mental Health

Davydov O.S.

Research Institute of General Pathology and Pathophysiology

Danilov An.B.

Sechenov First Moscow State Medical University (Sechenov University)

Devlikamova F.I.

Kazan State Medical Academy

Zhivolupov S.A.

Kirov Military Medical Academy

Iskra D.A.

St. Petersburg State Pediatric Medical University

Kamchatnov P.R.

Pirogov Russian National Research Medical University

Karakulova Yu.V.

Wagner Perm State Medical University

Karpova M.I.

South Ural State Medical University

Kozlov I.G.

Sechenov First Moscow State Medical University (Sechenov University);
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology;
Sechenov First Moscow State Medical University (Sechenov University)

Kurushina O.V.

Volgograd State Medical University

Rachin A.P.

National Association of Experts in Comorbid Neurology

Sivolap Yu.P.

Patrice Lumumba Peoples’ Friendship University of Russia

Churyukanov M.V.

Sechenov First Moscow State Medical University (Sechenov University);
Petrovsky National Research Center of Surgery

Shirokov V.A.

Ural State Medical University

Yakupov E.Z.

Professor Yakupov’s Neuroclinic, Professor Yakupov’s Education Center

Received:

27.12.2024

Accepted:

14.01.2025

Close metadata

References:

  1. WHO Fact sheet Low back pain. https://www.who.int/news-room/fact-sheets/detail/low-back-pain
  2. Wu A, March L, Zheng X, Huang J, Wang X, Zhao J, Blyth FM, Smith E, Buchbinder R, Hoy D. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Annals of Translational Medicine. 2020 Mar;8(6):299. PMID: 32355743; PMCID: PMC7186678. https://doi.org/10.21037/atm.2020.02.175
  3. Fatoye F, Gebrye T, Ryan CG, Useh U, Mbada C. Global and regional estimates of clinical and economic burden of low back pain in high-income countries: a systematic review and meta-analysis. Front Public Health. 2023 June 09;11:1098100. PMID: 37383269; PMCID: PMC10298167. https://doi.org/10.3389/fpubh.2023.1098100
  4. Gushcha A, Sharif S, Zileli M, Oertel J, Zygourakis CC, Yusupova AR. Acute back pain: Clinical and radiologic diagnosis: WFNS spine committee recommendations. World Neurosurgery: X. 2024;22:100278. https://doi.org/10.1016/j.wnsx.2024.100278
  5. Hnatešen D, Pavić R, Radoš I, Dimitrijević I, Budrovac D, Čebohin M, Gusar I. Quality of Life and Mental Distress in Patients with Chronic Low Back Pain: A Cross-Sectional Study. International Journal of Environmental Research and Public Health. 2022 Aug 26;19(17):10657. PMID: 36078372; PMCID: PMC9518072. https://doi.org/10.3390/ijerph191710657
  6. Christofaro DGD, Tebar WR, da Silva GCR, Oliveira MD, Cucato GG, Botero JP, Correia MA, Ritti-Dias RM, Lofrano-Prado MC, Prado WL. Depressive Symptoms Associated With Musculoskeletal Pain in Inactive Adults During COVID-19 Quarantine. Pain Management Nursing. 2022 Feb;23(1):38-42. Epub 2021 Aug 09. PMID: 34474996; PMCID: PMC8790053. https://doi.org/10.1016/j.pmn.2021.07.004
  7. Brawman-Mintzer O, Lydiard RB, Emmanuel N, Payeur R, Johnson M, Roberts J, Jarrell MP, Ballenger JC. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry. 1993 Aug;150(8):1216-8. PMID: 8328567. https://doi.org/10.1176/ajp.150.8.1216
  8. Bilterys T, Siffain C, De Maeyer I, Van Looveren E, Mairesse O, Nijs J, Meeus M, Ickmans K, Cagnie B, Goubert D, Danneels L, Moens M, Malfliet A. Associates of Insomnia in People with Chronic Spinal Pain: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2021 July 19;10(14):3175. PMID: 34300341; PMCID: PMC8304652. https://doi.org/10.3390/jcm10143175
  9. Freynhagen R, Muth-Selbach U, Lipfert P, Stevens MF, Zacharowski K, Tölle TR, von Giesen HJ. The effect of mirtazapine in patients with chronic pain and concomitant depression. Current Medical Research and Opinion. 2006 Feb;22(2):257-264. PMID: 16466597. https://doi.org/10.1185/030079906X80486
  10. Lévy E, Margolese HC. Migraine headache prophylaxis and treatment with low-dose mirtazapine. International Clinical Psychopharmacology. 2003 Sept;18(5):301-303. PMID: 12920393. https://doi.org/10.1097/01.yic.0000080803.87368.01
  11. Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology. 2004 May 25;62(10):1706-1711. PMID: 15159466. https://doi.org/10.1212/01.wnl.0000127282.90920.8c
  12. Miki K, Murakami M, Oka H, Onozawa K, Yoshida S, Osada K. Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain. 2016 Sept;157(9):2089-2096. PMID: 27218868; PMCID: PMC4988084. https://doi.org/10.1097/j.pain.0000000000000622
  13. Chang WJ. Muscle Relaxants for Acute and Chronic Pain. Physical Medicine and Rehabilitation Clinics of North America. 2020;31(2):245-254. 
  14. Price MR, Cupler ZA, Hawk C, Bednarz EM, Walters SA, Daniels CJ. Systematic review of guideline-recommended medications prescribed for treatment of low back pain. Chiropractic & Manual Therapies. 2022 May 13;30(1):26. PMID: 35562756; PMCID: PMC9101938. https://doi.org/10.1186/s12998-022-00435-3
  15. Cashin AG, Wand BM, O’Connell NE, Lee H, Rizzo RR, Bagg MK, O’Hagan E, Maher CG, Furlan AD, van Tulder MW, McAuley JH. Pharmacological treatments for low back pain in adults: an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews. 2023 Apr 04;4(4):CD013815. PMID: 37014979; PMCID: PMC10072849. https://doi.org/10.1002/14651858.CD013815.pub2
  16. Bennett RM. Emerging concepts in the neurobiology of chronic pain: Evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc. 1999;74:385-398. 
  17. Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain. 2011;152(3):2-15. 
  18. General characteristics of the drug Dorsumio. (In Russ.). https://www.valentapharm.com/products/psychoneurology/Dorsumio/
  19. Danilov AB, Yakupov EZ, Sivolap YuP, Kozlov IG, Shirokov VA. Mu ltivalent effect on chronic back pain: results of randomized clinical trials of Dorsumio. Russian Journal of Pain. 2024;22(3):63-73. (In Russ.). https://doi.org/10.17116/pain20242203163
  20. Rachin AP, Sharov MN, Karpov SM, Rachin SA, Prokofyeva YuS, Parsamyan RR. Khronicheskaya bol’ v spine: ot patogeneza k adekvatnoj farmakoterapii. Komorbidnaya nevrologiya. 2024;1(3):85-93. (In Russ.).
  21. Riederer P, Laux G, Nagatsu T, et al., eds. NeuroPsychopharmacotherapy. Springer Nature; 2022.
  22. Ono N, Kroin JS, Penn RD, Paice JA. Effects of intrathecal nonnarcotic analgesics on chronic tactile allodynia in rats: alpha 2-agonists versus somatostatin analog. Neurologia Medico-Chirurgica (Tokyo). 1997 Jan;37(1):6-10; discussion 10-11. PMID: 9046798. https://doi.org/10.2176/nmc.37.6
  23. Pei W, Zou Y, Wang W, Wei L, Zhao Y, Li L. Tizanidine exerts anti-nociceptive effects in spared nerve injury model of neuropathic pain through inhibition of TLR4/NF-κB pathway. International Journal of Molecular Medicine. 2018 Dec;42(6):3209-3219. Epub 2018 Sept 13. PMID: 30221670; PMCID: PMC6202089. https://doi.org/10.3892/ijmm.2018.3878
  24. Aghili SH, Manavi MA, Panji M, Farhang Ranjbar M, Abrishami R, Dehpour AR. Mirtazapine Improves Locomotor Activity and Attenuates Neuropathic Pain Following Spinal Cord Injury in Rats via Neuroinflammation Modulation. Neurochemical Research. 2024 Dec;49(12):3326-3341. Epub 2024 Sept 13. PMID: 39271550. https://doi.org/10.1007/s11064-024-04240-7
  25. Nishihara M, Arai YC, Yamamoto Y, Nishida K, Arakawa M, Ushida T, Ikeuchi M. Combinations of low-dose antidepressants and low-dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases. Pain Physician. 2013 Sept-Oct;16(5):E547-E552. PMID: 24077205.
  26. Meskar H, Aezzi G, Kiyasari AZ, Shafizad M, Jalalian F, Alderraji M. The effect of tizanidine on postoperative pain management after lumbar fusion surgery. Exp Appl Biomed Res. 2023;24:49-56. 
  27. Zhu L-L, Wang Y-H, Zhou Q. Tizanidine: Advances in Pharmacology & Therapeutics and Drug Formulations. Journal of Pain Research. 2024 Mar 21;17:1257-1271. PMID: 38529017; PMCID: PMC10962466. https://doi.org/10.2147/JPR.S461032
  28. Albers LJ. Handbook of psychiatric drugs. 2004.
  29. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. British Journal of Clinical Pharmacology. 2004 Mar;57(3):349-353. PMID: 14998432; PMCID: PMC1884447. https://doi.org/10.1046/j.1365-2125.2003.02028.x
  30. Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clinical Pharmacokinetics. 2000 June;38(6):461-474. PMID: 10885584. https://doi.org/10.2165/00003088-200038060-00001
  31. Guo J, Zhu X, Badawy S, Ihsan A, Liu Z, Xie C, Wang X. Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2. Current Drug Metabolism. 2021;22(1):40-49. PMID: 33397254. https://doi.org/10.2174/1389200221999210101233135
  32. Goncharov AS, Grigoriev AV, Globenko AA, Goncharov IS, Muratov KA, Yaroshenko DV, Sidorova AA, Kapashin AV, Kovchan OV, Bashkatova AI, Pasko MA. Pharmacokinetic parameters, safety and drug-drug interactions of mirtazapine and tizanidine, combined in the new original drug Dorsumio®. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(4):80-88. (In Russ.). https://doi.org/10.14412/2074-2711-2023-4-80-88
  33. Lamoure J. How Does Mirtazapine Induce Weight Gain? Medscape. March 06, 2009. https://www.medscape.com/viewarticle/588676?form=fpf
  34. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Reviews. 2001 Fall;7(3):249-264. PMID: 11607047; PMCID: PMC6494141. https://doi.org/10.1111/j.1527-3458.2001.tb00198.x
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.